Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Drug firm Glenmark Pharmaceuticals’ subsidiary Glenmark Generics has entered into a settlement and licence agreement with US-based Nycomed to resolve patent infringement lawsuit for fluticasone propionate lotion, used for treating skin pain and itch. Fluticasone propionate 0.05% lotion by Glenmark is generic version of Nycomed's 'Cultivate' lotion.
Under the terms of agreement, Glenmark will be able to market and distribute it's Fluticasone Propionate lotion under a royalty-bearing license from Nycomed US in March 2012.Nycomed had filed a patent infringement suit in the US District Court of New York in December, 2008, challenging Glenmark's ANDA for Fluticasone propionate lotion.The company believes it is entitled to 180 days exclusivity for the product as it is the first generic company to have filed an ANDA for the product.
Glenmark had earlier received final approval from the US health regulator for its generic Fluticasone propionate lotion. The product is used in treating skin pain and itching caused by eczema. According to IMS health sales data for the year ended December, 2010, 'Cultivate' lotion achieved annual sales of nearly $48 million in the American market, Glenmark.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |